SG301SC is a the first subcutaneous anti-CD38 monoclonal antibody therapeutic biological candidate to receive IND clearance in China and a Ph I clinical trial for the treatment of Systemic Lupus Erythematosus (SLE) is ongoing.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
